Table 2.

Standardized mortality ratio among patients with T1–2N0M0 breast cancer based on molecular subtypes.

	HR+/HER2+	HR−/HER2+	HR+/HER2−	HR−/HER2−
Overall mortality	7.18 (6.82–7.56)	8.79 (8.13–9.50)	5.23 (5.15–5.32)	9.90 (9.54–10.26)
Time after initial diagnosis
≤1	4.37 (3.79–5.02)	5.14 (4.13–6.32)	2.50 (2.37–2.64)	5.24 (4.72–5.81)
1–3	5.58 (5.09–6.10)	7.95 (7.01–8.98)	3.88 (3.76–4.00)	9.32 (8.80–9.87)
3–5	8.86 (8.05–9.72)	10.73 (9.22–12.40)	6.39 (6.20–6.59)	12.82 (11.98–13.71)
>5	15.12 (13.59–16.78)	17.58 (14.54–21.07)	11.89 (11.52–12.27)	16.73 (15.27–18.28)
Age at diagnosis, y
≤65	52.22 (47.21–57.62)	61.73 (53.82–70.46)	45.97 (44.11–47.88)	64.46 (60.75–68.34)
65–85	10.23 (9.49–11.02)	10.99 (9.76–12.34)	8.33 (8.14–8.53)	11.73 (11.09–12.39)
>85	2.97 (2.69–3.28)	3.20 (2.69–3.77)	2.66 (2.58–2.74)	3.10 (2.84–3.37)
Race
White	6.61 (6.24–7.00)	8.25 (7.55–9.00)	4.93 (4.84–5.02)	8.80 (8.43–9.18)
Black	9.35 (8.12–10.70)	11.01 (8.94–13.42)	7.50 (7.11–7.90)	15.25 (14.08–16.49)
Other	19.23 (15.25–23.93)	12.55 (8.97–17.09)	8.58 (7.93–9.26)	14.42 (12.03–17.15)
CVD mortality	4.78 (3.88–5.84)	4.27 (3.05–5.82)	3.78 (3.58–4.00)	4.95 (4.20–5.80)
Time after initial diagnosis
≤1	3.37 (1.89–5.56)	2.19 (0.60–5.62)	1.67 (1.37–2.01)	2.49 (1.45–3.99)
1–3	3.52 (2.38–5.03)	4.01 (2.25–6.62)	2.72 (2.46–3.01)	3.59 (2.66–4.75)
3–5	5.66 (3.76–8.18)	3.96 (1.90–7.28)	4.49 (4.07–4.95)	6.98 (5.23–9.13)
>5	10.15 (6.50–15.10)	8.60 (4.29–15.39)	8.80 (7.94–9.72)	11.50 (8.01–16.00)
Age at diagnosis, y
≤65	32.12 (21.51–46.13)	45.47 (25.99–73.85)	37.52 (32.92–42.58)	36.35 (26.80–48.19)
65–85	9.25 (7.87–10.81)	8.99 (6.81–11.65)	7.39 (7.04–7.76)	9.19 (7.96–10.55)
>85	2.79 (2.33–3.31)	2.85 (2.03–3.90)	2.57 (2.45–2.70)	2.63 (2.25–3.06)
Race
White	4.45 (3.91–5.04)	5.18 (4.17–6.35)	3.81 (3.68–3.95)	4.28 (3.83–4.77)
Black	7.20 (5.34–9.49)	7.20 (3.59–12.88)	6.31 (5.67–7.01)	8.34 (6.56–10.46)
Other	9.23 (5.56–14.42)	7.57 (3.27–14.91)	6.39 (5.45–7.44)	7.09 (4.20–11.20)